CD&R, Merck GHI, and McKesson Ventures invest oncology data and informatics company M2Gen

Clinical Conversation with The Cancer Letter

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

July 25, 2025

Vol.51 No.29

By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg

Conversation with The Cancer Letter

Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?

On July 4, President Donald Trump signed into law “The One Big Beautiful Bill Act,” which is expected to deal a massive blow to Medicaid coverage and leave millions without insurance by instituting a work requirement for beneficiaries.

July 25, 2025

Vol.51 No.29

By Sara Willa Ernst

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya

In a move that will have direct impact on approval of cancer drugs, George Francis Tidmarsh, an oncologist and a longtime pharmaceutical executive, was named director of the FDA Center for Drug Evaluation and Research.

July 25, 2025

Vol.51 No.29

By Claire Marie Porter

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

NCI announced that the paylines for R01 grants for established and new investigators are expected to drop to the 4th percentile—a historic low for the institute.

Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad

Laura LoomerVinay PrasadRight-wing activist Laura Loomer is demanding Vinay Prasad’s ouster from FDA, calling him a “saboteur” and “trojan [sic] horse” of the administration’s “Make America Healthy Again” initiative.

July 25, 2025

Vol.51 No.29

By Claire Marie Porter

CD&R, Merck GHI, and McKesson Ventures invest oncology data and informatics company M2Gen

YOU MAY BE INTERESTED IN

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya

City of Hope brings evidence-based approaches to integrative oncology

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad

Renew today!

Subscriber content

Never miss an issue!

Login

CD&R, Merck GHI, and McKesson Ventures invest oncology data and informatics company M2Gen

YOU MAY BE INTERESTED IN

Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out

Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER directorHis appointment came out of “proximity” to Makary and Bhattacharya

City of Hope brings evidence-based approaches to integrative oncology

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad

Never miss an issue!

Login

Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya